drug_type
RELEVANT_DRUG
intervention_type
Cellular gene therapy (CAR T cells)
drug_description
Autologous CAR T-cell gene therapy in which patient T cells are engineered to express two fully human CARs: anti-CD19 with CD28/CD3ζ signaling and anti-CD20 with 4-1BB/CD3ζ signaling to enhance activation and persistence and reduce antigen-loss escape.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express two CARs: an anti‑CD19 CAR with CD28/CD3ζ signaling and an anti‑CD20 CAR with 4‑1BB/CD3ζ signaling. Upon binding CD19 or CD20 on B cells, the CARs activate T‑cell cytotoxicity and cytokine release to kill malignant B cells; CD28 promotes rapid activation/expansion and 4‑1BB enhances persistence. Dual antigen targeting is intended to reduce antigen‑loss escape and results in on‑target B‑cell aplasia.
drug_name
Anti-CD19/Anti-CD20 bicistronic CAR T cells (Hu1928-Hu20BB-Long)
nct_id_drug_ref
NCT05797233